SOURCE: Avisio Inc.

February 11, 2010 08:30 ET

Avisio, Inc. Forms OlFactor Laboratories, Inc. to Acquire Exclusive License to Patent Pending Technology From University of California, Riverside

Company to Commercialize New Technology for Insect Repellent and Trap Markets

RIVERSIDE, CA--(Marketwire - February 11, 2010) - OlFactor Laboratories, Inc. (OLI), a majority owned subsidiary of Avisio, Inc. (PINKSHEETS: AVIC), announced today that the company has acquired an exclusive license to patent pending technology from UC Riverside. The technology is based on an advanced scientific understanding of how two-winged blood-feeding insects, e.g. mosquitos and black flies, utilize their olfactory neurons to detect carbon dioxide (CO2) emissions from animals and humans. CO2, which is a major component in emitted or expirated breath by a human or animal, attracts the insect to its prey.

Developed by Anandasankar Ray, Ph.D., Assistant Professor of UC Riverside's Department of Entomology, the technology can be used as a repellent by inhibiting the detection of CO2 or as a trap by stimulating the detection of CO2. This radical new approach to fighting the transmission of infectious disease from blood-feeding insects is inexpensive and easy to produce, and uses chemicals that are safe and effective at the low concentrations required for these applications.

"We are excited to be working with Dr. Ray and his team at UC Riverside," said Amro Albanna, CEO of OlFactor Laboratories, Inc. and Avisio, Inc. "We look forward to shepherding the technology from its current technical feasibility status to full commercialization."

"We are fortunate to have a partner that understands the impact this new technology may have on millions of people around the world," said Craig Sheward, UC Riverside's Assistant Vice Chancellor for Technology Commercialization. "The company's ability to take this technology from the lab to a commercially viable product is of paramount importance as we move forward."

About University of California, Riverside

The University of California, Riverside (www.ucr.edu) is a doctoral research university, a living laboratory for groundbreaking exploration of issues critical to Inland Southern California, the state and communities around the world. Reflecting California's diverse culture, UCR's enrollment of over 19,000 is expected to grow to 21,000 students by 2020. The campus is planning a medical school and has reached the heart of the Coachella Valley by way of the UCR Palm Desert Graduate Center. The campus has an annual statewide economic impact of more than $1 billion.

About OlFactor Laboratories, Inc.

OlFactor Labortories, Inc. is a majority owned subsidiary of Avisio formed to commercialize patented technnology that brings a novel approach to combatting the spread of infectious diseases caused by blood-feeding insects. The technology, utilizing scientific understanding of how insect olfactory systems dectect carbon dioxide, can be used to activate CO2 or repel CO2 , depending on the end application.

About Avisio, Inc.

Avisio, Inc. is a publicly-traded technology commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses. Avisio plans to create a new majority-owned private subsidiary around each asset and to support each business with experienced management teams, best-of-breed commercialization processes and resources, and access to global capital sources. For more information, please visit www.avisioinc.com

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based largely on expectations and projections about future events and future trends and are subject to numerous assumptions, risks and uncertainties, which change over time. Avisio's actual results could differ materially from those anticipated in forward-looking statements and you should not place any undue reliance on such forward-looking statements.

The forward-looking statements in this news release are made as of the date hereof, and Avisio does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after the date hereof.

Contact Information